Clinical significance of Janus Kinase inhibitor selectivity
EH Choy - Rheumatology, 2019 - academic.oup.com
Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the
outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular …
outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular …
A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19
Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …
Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications
PC Taylor, T Bieber, R Alten, T Witte, J Galloway… - Advances in …, 2023 - Springer
Abstract Introduction Baricitinib, a Janus kinase (JAK) 1/2 inhibitor, is an approved treatment
for rheumatoid arthritis (RA), atopic dermatitis (AD), and alopecia areata (AA). Further …
for rheumatoid arthritis (RA), atopic dermatitis (AD), and alopecia areata (AA). Further …
[HTML][HTML] Janus kinase inhibitors for the therapy of atopic dermatitis
S Traidl, S Freimooser, T Werfel - Allergologie select, 2021 - ncbi.nlm.nih.gov
The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous
inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual …
inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual …
A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
Baricitinib, an oral selective Janus kinase (JAK) 1/JAK2 inhibitor, is approved as
monotherapy or in combination with methotrexate for treating adults with moderate-to-severe …
monotherapy or in combination with methotrexate for treating adults with moderate-to-severe …
JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data
R Harrington, SA Al Nokhatha… - Journal of inflammation …, 2020 - Taylor & Francis
Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to
emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted …
emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted …
Janus kinase inhibitors in dermatology: Part I. A comprehensive review
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular
signaling pathway is utilized by many proinflammatory molecules to mediate downstream …
signaling pathway is utilized by many proinflammatory molecules to mediate downstream …
Start RA treatment–Biologics or JAK-inhibitors?
R Caporali, S Germinario, D Kacsándi, E Choy… - Autoimmunity …, 2023 - Elsevier
Abstract Janus Kinase inhibitors (JAKis) have been approved for the treatment of
Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatments with …
Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatments with …
Systemic treatment of psoriasis with JAK inhibitors: a review
Psoriasis is a prevalent chronic inflammatory disease. The inflammatory response is driven
by T cells and mediated by multiple cytokines such as tumor necrosis factor and the …
by T cells and mediated by multiple cytokines such as tumor necrosis factor and the …
Janus kinase inhibitors for rheumatoid arthritis
K Yamaoka - Current opinion in chemical biology, 2016 - Elsevier
Highlights•Jakinibs are the new class of DMARDs with unprecedented effect.•Jakinibs show
clinical efficacy in the early phase of treatment of RA.•Besides the efficacy of Jakinibs, rate of …
clinical efficacy in the early phase of treatment of RA.•Besides the efficacy of Jakinibs, rate of …